Table 4.

Multivariate Cox proportional hazard model for the relative hazard of AIDS progression and the combination of AIDS progression or death

	AIDS progression		AIDS progression or death
	RHa	95% CI	RH	95% CI
PPD-positiveb
Placebo (n = 464)	1.0	—	1.0	—
6H (n = 536)	0.95	0.68–1.32	1.02	0.80–1.30
3HR (n = 556)	0.83	0.59–1.17	0.91	0.71–1.17
3HRZ (n = 462)	0.76	0.52–1.10	0.87	0.67–1.14
3HR & 3HRZ (n = 1,018)	0.80	0.59–1.08	0.90	0.72–1.12
PPD-positivec
6H (n = 536)	1.0	—	1.0	—
3HR (n = 556)	0.88	0.63–1.23	0.89	0.70–1.14
3HRZ (n = 462)	0.81	0.56–1.17	0.86	0.66–1.12
3HR & 3HRZ (n = 1,018)	0.85	0.63–1.14	0.88	0.71–1.09
Anergic
Placebo (n = 323)	1.0	—	1.0	—
6H (n = 395)	0.81	0.56–1.15	1.00	0.78 – 1.28

Note: Event = major sign or ≥3 minor signs or death, whichever comes first. RH = relative hazard; CI = confidence interval.

^aThe relative hazard is adjusted for sex, age, hemoglobin, body mass index, SGOT, absolute lymphocyte count and the number of HIV-related signs at baseline in a Cox proportional hazards regression model; Baseline sign is the number of HIV-related signs at baseline: {Karnofsky score ≤ 60, TB, esophageal candidiasis, VZV, Kaposi's sarcoma, oral candidiasis, pruritic papules, herpes simplex, oral herpes simplex (oral)}.

^bPlacebo is the reference group.

^c6H is the reference group.